2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Consensus Target Price from Analysts

2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) has received a consensus recommendation of "Hold" from the seven research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $6.83.

TSVT has been the subject of several analyst reports. Leerink Partners restated a "market perform" rating and issued a $5.00 target price (down from $9.00) on shares of 2seventy bio in a report on Tuesday. Weiss Ratings restated a "sell (d-)" rating on shares of 2seventy bio in a research note on Friday.

2seventy bio Trading Up 76.6 %

NASDAQ TSVT traded up $2.15 during trading on Monday, hitting $4.95. 30,254,277 shares of the company traded hands, compared to its average volume of 942,272. 2seventy bio has a 12 month low of $2.29 and a 12 month high of $5.99. The business has a fifty day simple moving average of $2.60 and a 200 day simple moving average of $3.68. The company has a market capitalization of $255.10 million, a P/E ratio of -2.66 and a beta of 1.73.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TSVT. Toronto Dominion Bank acquired a new stake in 2seventy bio during the fourth quarter worth about $2,352,000. Western Standard LLC lifted its position in 2seventy bio by 175.7% in the fourth quarter. Western Standard LLC now owns 788,350 shares of the company's stock worth $2,318,000 after purchasing an additional 502,419 shares during the period. Stonepine Capital Management LLC boosted its stake in 2seventy bio by 200.0% during the fourth quarter. Stonepine Capital Management LLC now owns 300,000 shares of the company's stock worth $882,000 after buying an additional 200,000 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in 2seventy bio in the 4th quarter valued at $913,000. Finally, ProShare Advisors LLC acquired a new position in shares of 2seventy bio in the 4th quarter valued at $48,000. Institutional investors own 93.90% of the company's stock.

Remove Ads

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.